# Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer

> **NCT01433614** · PHASE3 · COMPLETED · sponsor: **Thomas Hatschek** · enrollment: 304 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Paclitaxel
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01433614
- **Lead sponsor:** Thomas Hatschek
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2006-06
- **Final completion:** 2013-12
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2015-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01433614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01433614, "Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01433614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*